Go online to PeerView.com/UKX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to work collaboratively to overcome the complexities of myelodysplastic syndromes (MDS) diagnosis, prognostic assessment, and individualized therapy selection? Find out by joining pathology and hematology-oncology experts in this activity, based on a live symposium, that offers case-based guidance on modern, personalized treatment for patients with different disease presentations. Throughout, the experts illustrate how to address important disease symptoms (such as anemia) and reinforce the core pathology principles for optimized diagnosis and communication of test results with a goal in prodigy enhanced, more personalized care. Upon completion of this activity, participants should be better able to: Discuss molecular and pathologic features, risk factors, and evidence supporting the use of novel therapeutics to inform diagnostic assessment and personalized care of MDS; Employ appropriate molecular/pathologic testing to establish a diagnosis of MDS or a specific subtype informed by clinical, molecular, and cytogenetic findings; and Develop collaborative team-based treatment plans for patients with MDS based on molecular testing results, pathologic risk assessment, and current guidelines.